LUCENTIS
RANIBIZUMAB · by NOVARTIS
Composition
Inj: Ranibizumab 10 mg/ ml; solution for intravitreal injection; 0.23 ml vial.
Indications & Dosage
Neovascular (wet) age-related macular degeneration: BY INTRAVITREAL INJ: Adult: 500 mcg once a month, to be administered into the affected eye, monitor visual acuity monthly, continue treatment until visual acuityis stable for 3 consecutive months, thereafter monitor visual acuity monthly, if necessary subsequent doses may be given at least 1 month apart; discontinue treatment if no improvement in visual acuity after initial 3 injections. Diabetic macular oedema, Macular oedema secondary to retinal vein occlusion: BY INTRAVITREAL INJ: Adult: Initially 500 mcg once a month, to be administered into the affected eye, monitor visual acuity monthly, continue treatment until visual acuityis stable for 3 consecutive months, thereafter monitor visual acuity monthly, if necessary subsequent doses may be given at least 1 month apart; discontinue treatment if no improvement in visual acuity after initial 3 injections. Choroidal neovascularisation secondary to pathologic Myopia: BY INTRAVITREAL INJ: Adult: Initially 500 mcg, to be administered as a single injection into the affected eye, monitor for disease activity monthly for first 2 months, then at least every 3 months thereafter during the first year, then as required, if necessary subsequent doses may be given at least 1 month apart. Concomitant treatment of diabetic macular oedema, or macular oedema secondary to branch retinal vein occlusion, with laser photocoagulation: BY INTRAVITREAL INJ: Adult: 500 mcg, to be administered at least 30 minutes after laser photocoagulation.
Contraindications
Severe intra-ocular inflammation, ocular or periocular infection, signs of irreversible, ischaemic visual function loss in patients with retinal vein occlusion
Precautions
Pregnancy & lactation, active systemic infection, diabetic macular oedema due to type 1 diabetes, diabetic patients with HbA1c over 12%, history of stroke, history of transient ischaemic attack, patients at risk of retinal pigment epithelial tear, previous intravitreal injections, proliferative diabetic retinopathy, retinal detachment or macular hole, uncontrolled hypertension. Monitor intra-ocular pressure, perfusion of the optic nerve head, and for signs of ocular infection following injection.Monitor visual acuity, see individual indications and dosefor frequency.
Side Effects
Anterior chamber flare, anxiety, arthralgia, anaemia, blepharitis, cataract, conjunctival disorders, conjunctivitis, eye haemorrhage, eyelid oedema, headache, iridocyclitis, iritis, nasopharyngitis, nausea, ocular discomfort, photophobia, photopsia, posterior capsule opacification, punctuate keratitis, raised intra-ocular pressure, retinal disorders, urinary tract infection, uveitis, visual disturbance, vitreous disorders, skin reactions. Rare: Blindness, corneal disorders, hyphaema, hypopyon, iris adhesion, keratopathy